PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Up 20.5% in March

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) saw a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 1,485,129 shares, a growth of 20.5% from the February 26th total of 1,232,783 shares. Approximately 3.0% of the company’s stock are short sold. Based on an average daily volume of 1,544,359 shares, the short-interest ratio is currently 1.0 days.

PMV Pharmaceuticals Price Performance

Shares of PMVP stock opened at $1.24 on Wednesday. The firm has a market cap of $66.13 million, a P/E ratio of -0.83 and a beta of 1.27. PMV Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.88. The firm has a fifty day moving average of $1.29 and a two-hundred day moving average of $1.31.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Friday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. On average, sell-side analysts expect that PMV Pharmaceuticals will post -1.06 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PMV Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, PMV Pharmaceuticals currently has an average rating of “Sell”.

Institutional Trading of PMV Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of PMVP. Seven Fleet Capital Management LP bought a new stake in shares of PMV Pharmaceuticals in the 4th quarter valued at approximately $79,000. XTX Topco Ltd lifted its stake in PMV Pharmaceuticals by 144.3% during the fourth quarter. XTX Topco Ltd now owns 104,485 shares of the company’s stock worth $131,000 after purchasing an additional 61,723 shares during the last quarter. Tang Capital Management LLC lifted its stake in PMV Pharmaceuticals by 3.2% during the fourth quarter. Tang Capital Management LLC now owns 4,940,000 shares of the company’s stock worth $6,175,000 after purchasing an additional 154,799 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in PMV Pharmaceuticals by 33.7% in the fourth quarter. Bridgeway Capital Management LLC now owns 428,853 shares of the company’s stock worth $536,000 after purchasing an additional 108,200 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its holdings in PMV Pharmaceuticals by 349.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after purchasing an additional 21,334 shares during the period. Institutional investors and hedge funds own 90.20% of the company’s stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.